We appreciated the recently published paper of Crotti and coworkers in which the authors reported a patient with tumor-induced osteomalacia (TIO) treated with burosumab for over 2 years for a tumor located in the pre-sacral region that recurred 18 months after excision. Recurrence was associated with decline of serum phosphate (SP) and increase of serum FGF23. After 4 years of treatment with calcitriol and phosphorus supplements without SP normalization, burosumab was started “at the dose of 0.3 mg/kg/month.” The starting dose of burosumab used in this patient was the same used in two previous trials on TIO adult patients. However, in these studies, the overall effects were not completely satisfactory.

Appropriate dosing of burosumab in tumor-induced osteomalacia / Colangelo, Luciano; Sonato, Chiara; Riminucci, Mara; Corsi, Alessandro; Minisola, Salvatore. - In: OSTEOPOROSIS INTERNATIONAL. - ISSN 0937-941X. - 34:2(2023). [10.1007/s00198-022-06617-2]

Appropriate dosing of burosumab in tumor-induced osteomalacia

Colangelo, Luciano
Primo
Writing – Original Draft Preparation
;
Sonato, Chiara
Secondo
;
Riminucci, Mara;Corsi, Alessandro
Penultimo
Writing – Original Draft Preparation
;
Minisola, Salvatore
Ultimo
2023

Abstract

We appreciated the recently published paper of Crotti and coworkers in which the authors reported a patient with tumor-induced osteomalacia (TIO) treated with burosumab for over 2 years for a tumor located in the pre-sacral region that recurred 18 months after excision. Recurrence was associated with decline of serum phosphate (SP) and increase of serum FGF23. After 4 years of treatment with calcitriol and phosphorus supplements without SP normalization, burosumab was started “at the dose of 0.3 mg/kg/month.” The starting dose of burosumab used in this patient was the same used in two previous trials on TIO adult patients. However, in these studies, the overall effects were not completely satisfactory.
2023
tumor-induced osteomalacia (TIO); burosumab; serum phosphate (SP)
01 Pubblicazione su rivista::01f Lettera, Nota
Appropriate dosing of burosumab in tumor-induced osteomalacia / Colangelo, Luciano; Sonato, Chiara; Riminucci, Mara; Corsi, Alessandro; Minisola, Salvatore. - In: OSTEOPOROSIS INTERNATIONAL. - ISSN 0937-941X. - 34:2(2023). [10.1007/s00198-022-06617-2]
File allegati a questo prodotto
File Dimensione Formato  
Colangelo_Appropriate dosing_2022.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 322.3 kB
Formato Adobe PDF
322.3 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1661854
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact